Charles River Laboratories: The Invisible Bouncer Before FDA Approval

As a leading contract research organization, Charles River has been involved in over 80% of all recently FDA-approved drugs in the preclinical phase, thereby forming the backbone of early drug development. The business model combines legally mandated safety studies with high-margin, recurring sales of testing kits for the quality control of sterile pharmaceuticals. The company benefits in the long term from the increasing outsourcing of research by Big Pharma, as well as the boom in complex cell and gene therapies that require particularly...